- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06159062
A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 162 With a Single Ascending Dose in Subjects With Chronic Hepatitis B Virus Infection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multi-center, randomized, double-blind and placebo-controlled dose escalation study design.
The dose-escalation stage will be conducted sequentially at 3 dose cohorts, which are 50 mg in the pre-test, 75 mg and 100 mg in the formal test.
Two subjects with chronic HBV infection will be enrolled in the 50 mg dose cohort and all will be given the investigational product 162.
Four subjects with chronic HBV infection will be enrolled in the 75 mg and 100 mg dose cohorts, respectively. Subjects in each cohort will be randomized 3:1 to receive a single ascending dose of 162 or placebo.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jinyu Yang
- Phone Number: +86 18258235083
- Email: jyyang10@mail.yst.com.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1. Able and willing to provide written informed consent and to comply with the study protocol according to ICH and local regulations.
2. Positive serum HBsAg and/or HBV DNA status for > 6 months prior to screening (two documented positive HBsAg and/or HBV DNA tests at least 6 months apart, one of which is at screening) or previous liver biopsy results with chronic HBV infection.
3. On Nucleos(t)ide analogs therapy for at least 3 months without an interruption of 7 or more consecutive days before the screening, and expected to remain on the same Nucleos(t)ide analogs for the duration of study participation.
4. 500 ≤ HBsAg ≤ 3,000 IU/mL, HBV DNA ≤ 20 IU/mL and ALT ≤ 3×ULN. 5. A male subject must agree to use adequate contraception from screening through at least 24 weeks after the dose of investigational product. Refer to Section 5.5 for more information on highly effective methods of contraception.
6. Women of childbearing potential must have a negative pregnancy test prior to the dosing administration, and agree to use adequate contraception from screening through at least 24 weeks after the dose of investigational product. A female subject of non-childbearing potential will have had at least 12 continuous months of natural (spontaneous) amenorrhoea, follicle stimulating hormone (FSH) level > 40 mIU/mL at screening, and an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms); or have had surgical bilateral oophorectomy, hysterectomy or bilateral tubal ligation beyond 6 weeks prior to screening. Refer to Section 5.5 for more information on highly effective methods of contraception.
Exclusion Criteria:
1. Patients who had history of anaphylaxis against the active ingredients or excipients of the investigational product 162.
2. History of allergic reactions to monoclonal antibodies or antibody fragments.
3. History or presence of clinical significant liver disease other than chronic HBV infection (e.g., autoimmune hepatitis, alcoholic liver disease, non-alcoholic steatohepatitis).
4. Patients who have impaired cardiac function or clinically significant cardiac diseases, including any of the following: New York Heart Association class III-IV for cardiac insufficiency; Patients with poorly controlled arrhythmia: QTc interval > 480 ms calculated by Fridericia's formula, or congenital syndrome of prolonged QT interval; Any of the following within 6 months prior to the screening: myocardial infarction, severe or unstable angina, congestive heart failure, cerebrovascular accident (including transient ischemic attack), symptomatic pulmonary embolism or other clinically significant thromboembolic disease, or coronary artery bypass graft; Patients with other clinically significant cardiovascular disease who were assessed as unsuitable for this study by the investigator.
5. Patients with uncontrolled hypertension (systolic blood pressure ≥ 150 mm Hg and/or diastolic blood pressure ≥ 100 mm Hg) or previous hypertensive crisis or hypertensive encephalopathy.
6. Patients with other active infections other than HBV infection requiring continual treatment with antibiotics or antivirals (except for clinically insignificant temporary infection such as cold), or positive for hepatitis C virus (HCV) or human immunodeficiency virus (HIV) antibodies at screening.
7. Patients with history of hepatitis A virus (HAV), hepatitis D virus (HDV) or hepatitis E virus (HEV).
8. Patients with history of malignant tumor within 5 years except cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of uterine cervix.
9. History or presence of immune-mediated diseases, including but not limited to idiopathic thrombocytopenic purpura, systemic lupus erythematosus, rheumatoid arthritis.
10. Liver biopsy, Fibroscan or equivalent test obtained within the past 6 months demonstrating liver with evidence of progressive fibrosis or cirrhosis ( Metavir 3, recommended cut-off for fibroscan 8.5 kPa).
11. Evidence of liver cirrhosis or decompensated liver disease such as Child-Pugh Class B or C, ascites, esophageal or gastric varices, hepatic encephalopathy or portal hypertension.
12. History of or suspicion of hepatocellular carcinoma or alpha fetoprotein (AFP) > 50 ng/mL at screening.
13. History of allogenic transplantation of organs, bone marrow or stem cell. 14. Any other concomitant disease, condition or treatment that could interfere with the conduct of the study or that would, in the opinion of the Investigator or Sponsor, pose an unacceptable risk to the subject in the study or interfere with the interpretation of study data.
15. Those who received blood transfusion, albumin, recombinant human thrombopoietin, or colony-stimulating factor therapy within 2 weeks prior to screening 16. Patients who have not sufficient baseline organ function and whose laboratory data meet the following criteria at enrollment: Absolute neutrophil count (ANC) < 2.0×109/L; Serum albumin < 35 g/L; Total bilirubin > 1.5×ULN; International normalized ratio (INR) > 1×ULN; Hemoglobin < 100 g/L; Platelets < 80×109/L; Creatinine clearance < 50 mL/min. 17. Patients who had received an immunosuppressant, immunity-modifying drug (e.g., interferon, thymosin agents), cytotoxic chemotherapy that can affect their immune system, or radiation therapy within 6 months prior to the dosing of investigational product, except for the following treatments: a) topical or inhaled corticosteroids; b) short-term (treatment duration up to 7 days) use of systemic glucocorticoids for prevention or treatment of non-autoimmune allergic diseases.
18. Those who have received live or attenuated vaccines (e.g., measles, mumps, rubella, varicella, yellow fever, rabies, BCG, typhoid vaccine, etc.) within 4 weeks before screening, or any covid-19 vaccine within 2 weeks before screening.
19. Those who underwent major surgery within 4 weeks before screening, or plan to undergo major surgery during the study.
20. Those who are participating in other clinical studies, or currently not participating in a study and have been dosed in another clinical study 4 weeks prior to screening, or previous treatment with an investigational agent for chronic HBV infection 6 months prior to screening.
21. Pregnant or lactating women. 22. Those who are determined disqualified to join clinical studies by investigator for other causes.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 162
The dose-escalation stage will be conducted sequentially at 3 dose cohorts, which are 50 mg in the pre-test, 75 mg and 100 mg in the formal test. Two subjects with chronic HBV infection will be enrolled in the 50 mg dose cohort and all will be given the investigational product 162. Four subjects with chronic HBV infection will be enrolled in the 75 mg and 100 mg dose cohorts, respectively. Subjects in each cohort will be randomized 3:1 to receive a single ascending dose of investigational product 162 or placebo. |
The investigational product 162 is a novel monoclonal antibody targeting HBsAg.
|
Placebo Comparator: Placebo
The dose-escalation stage will be conducted sequentially at 3 dose cohorts, which are 50 mg in the pre-test, 75 mg and 100 mg in the formal test. Two subjects with chronic HBV infection will be enrolled in the 50 mg dose cohort and all will be given the investigational product 162. Four subjects with chronic HBV infection will be enrolled in the 75 mg and 100 mg dose cohorts, respectively. Subjects in each cohort will be randomized 3:1 to receive a single ascending dose of investigational product 162 or placebo. |
Placebo do not consist any active ingredients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse event (consists of dose limited toxicity)
Time Frame: From the participant receives the investigational product to 28 days after the investigational product administered
|
incidence and severity of adverse events
|
From the participant receives the investigational product to 28 days after the investigational product administered
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the concentration curve
Time Frame: Within 30 minutes before the dosing administration to 648 hours after the start of the dosing administration
|
Area under the concentration curve
|
Within 30 minutes before the dosing administration to 648 hours after the start of the dosing administration
|
Maximum concentration
Time Frame: Within 30 minutes before the dosing administration to 648 hours after the start of the dosing administration
|
Maximum plasma concentration of 162
|
Within 30 minutes before the dosing administration to 648 hours after the start of the dosing administration
|
Half-life
Time Frame: Within 30 min before the dosing administration to 648 h after the start of the dosing administration
|
Half-life fo 162 eliminates from plasma
|
Within 30 min before the dosing administration to 648 h after the start of the dosing administration
|
Time of maximum concentration
Time Frame: Within 30 minutes before the dosing administration to 648 hours after the start of the dosing administration
|
Time of maximum concentration of 162 in plasma
|
Within 30 minutes before the dosing administration to 648 hours after the start of the dosing administration
|
Concentration of serum Hepatitis B surface antigen (HBsAg)
Time Frame: Within 30 minutes before the dosing administration to 648 hours after the start of the dosing administration
|
The concentration of serum Hepatitis B surface antigen (HBsAg)
|
Within 30 minutes before the dosing administration to 648 hours after the start of the dosing administration
|
Concentration of serum Hepatitis B virus DNA
Time Frame: Within 30 minutes before the dosing administration to 648 hours after the start of the dosing administration
|
The concentration of serum Hepatitis B virus DNA
|
Within 30 minutes before the dosing administration to 648 hours after the start of the dosing administration
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Blood-Borne Infections
- Disease Attributes
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Chronic Disease
- Infections
- Communicable Diseases
- Hepatitis B
- Hepatitis
- Hepatitis A
- Virus Diseases
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Herpesviridae Infections
Other Study ID Numbers
- YST-162-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis B Virus Infection
-
Enanta Pharmaceuticals, IncTerminatedChronic Hepatitis B Virus InfectionNew Zealand
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Sun Yat-sen UniversityRecruitingChronic Hepatitis B Virus InfectionChina
-
Bristol-Myers SquibbCompletedChronic Hepatitis C Virus Infection | Chronic Hepatitis B Virus InfectionUnited States
-
Hoffmann-La RocheTerminatedHepatitis B Virus InfectionUnited Kingdom, Hong Kong, Korea, Republic of, Taiwan, Poland, Bulgaria, New Zealand
-
Enanta Pharmaceuticals, IncPharmaceutical Research AssociatesCompletedChronic HBV InfectionUnited States, Canada
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bMoldova, Republic of, Ukraine
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruiting
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.RecruitingChronic Hepatitis bChina
-
Janssen Sciences Ireland UCCompletedHepatitis BUnited States, Korea, Republic of, France, Belgium, Italy, Taiwan, United Kingdom, Thailand, Malaysia, China, Spain, Canada, Germany, Japan, Russian Federation, Turkey, Ukraine, Poland, Hong Kong
Clinical Trials on 162
-
Vanda PharmaceuticalsCompleted
-
Vanda PharmaceuticalsCompleted
-
UniQure Biopharma B.V.Not yet recruiting
-
M.D. Anderson Cancer CenterArray BioPharmaTerminated
-
Vanda PharmaceuticalsCompletedCircadian Rhythm Sleep DisordersUnited States
-
Vanda PharmaceuticalsActive, not recruitingNon 24 Hour Sleep Wake DisorderFrance
-
Cancer Institute and Hospital, Chinese Academy...Beijing Shenogen Biomedical Co., LtdCompleted
-
Vanda PharmaceuticalsCompletedNon-24-Hour Sleep-Wake DisorderUnited States
-
Vanda PharmaceuticalsCompleted
-
Vanda PharmaceuticalsCompletedNon-24-Hour Sleep-Wake DisorderUnited States, Germany